🇺🇸 FDA
Pipeline program

Mesenchymal stem cells

MSC-cGVHD-2020

Phase 2 mab active

Quick answer

Mesenchymal stem cells for Chronic Graft-versus-host Disease is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Chronic Graft-versus-host Disease
Phase
Phase 2
Modality
mab
Status
active

Clinical trials